## **Special Issue**

# Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease

## Message from the Guest Editor

Non-alcoholic fatty liver disease (NAFLD) is described as the existence of fat vesicles (mostly triglycerides) in hepatocytes, encompassing the simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. NAFLD comprises non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NAFLD is linked to an increased risk of liver-related morbidity and death, as well as cardiovascular disease. diabetes, and non-liver-related cancer. NAFLD is linked to obesity, glucose homeostasis abnormalities, and metabolic syndrome (but it can also be present in persons who do not have symptoms of metabolic syndrome). This Special Issue aims to unravel the process of NAFLD, explore its novel signaling pathways and regulatory mechanisms, and gain insights into the NAFLD complications in the human body and health, which will help us to develop new drugs and methods to combat NAFLD-related diseases. We welcome original research and reviews on new drugs and strategies targeting NAFLD.

### **Guest Editor**

Prof. Dr. Ahmed E Abdel Moneim

Department of Zoology and Entomology, Helwan University, Cairo, Egypt

## Deadline for manuscript submissions

closed (15 January 2023)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/129942

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

